IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Merial Limited v Intervet International B.V. [2016] APO 39
Patent Application: 2006289102
Title:PCV-2 vaccine
Patent Applicant: Intervet International B.V.
Opponent: Merial Limited
Delegate: Dr B. Akhurst
Decision Date: 27 June 2016
Hearing Date: 6 April 2016
Catchwords: PATENTS – section 59 opposition to grant of a patent – manner of manufacture – a feature of the claims is not obvious of the face of the specification – manner of manufacture ground not established – novelty – the prior art documents relied on do not provide clear and unmistakable directions to the combination of features in the claims – lack of novelty not established – inventive step – the person skilled in the art would directly be led as a matter of course to try the Blanchard PCV-2 ORF-2 protein in doses encompassed by the opposed claims with a reasonable expectation that it might well solve the problem – the claims lack an inventive step – useful – lack of utility not established – fair basis – not established
Representation: Patent attorney for the applicant: David Myers of Spruson & Ferguson.
Counsel for the opponent: Jon Gottshall.
Patent attorney for the opponent: Jane Hutchison and Jenny Petering of FB Rice.
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2006289102
Title:PCV-2 vaccine
Patent Applicant: Intervet International B.V.
Date of Decision: 27 June 2016
DECISION
The opposition is successful. Claims 1-6 and 8-11 lack an inventive step.
Intervet International B.V. has 2 months from the date of this decision to propose amendments to the claims.
I make no award of costs.
REASONS FOR DECISION
Background
Intervet International B.V. (Intervet) filed patent application 2006289102 via the PCT on 8 September 2006, claiming priority from application EP 05108299.8 filed on 9 September 2005. Following examination, acceptance of the application was advertised on 15 December 2011.
Merial Limited (Merial) filed a notice of opposition on 15 March 2012 and a statement of grounds and particulars (SGP) on 15 June 2012. After extensions of time were granted at each stage, evidence in support was completed on 15 February 2013 and evidence in answer on 16 June 2014. Evidence in reply was completed on 15 September 2014. On 23 March 2015, Merial filed requests to amend the SGP and to file further evidence, accompanied by the evidence. The amendment request and the further evidence were allowed on 16 April 2015 and 9 June 2015, respectively. Intervet filed responding evidence on 10 August 2015.
The matter was heard on 6 April 2016 in Canberra.
The Evidence
Evidence in support consisted of declarations by:
- Christopher Chase dated 13 November 2012 (Chase#1) with exhibits CC-1 to CC-8
- Richard Bevan dated 13 February 2013 (Bevan#1) with exhibits RB-1 and RB-2
Evidence in answer consisted of a declaration by:
- Mark A. O’Dea (O’Dea#1) dated 16 June 2014 with exhibits MOD-1 to MOD-12
Evidence in reply consisted of declarations by:
- Christopher Chase dated 11 September 2014 (Chase#2
Keep reading for free
Create a free CaseChat account to read Merial Limited v Intervet International B.V and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2016] APO 39
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.